Clinical Trial Update: ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluating ZD6474 (vandetanib) alone and in combination with retinoic acid for pediatric neuroblastoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroblastoma

Drugs mentioned

• Retinoic acid (all-trans retinoic acid)
• ZD6474 (vandetanib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Neuroblastoma | Phase 1 | Status: TERMINATED